NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 83 resultados LastUpdate Última actualización 22/05/2019 [15:05:00] pdf PDF

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days

Página1 de 4 nextPage   por página


STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS

NºPublicación: US2019142957A1 16/05/2019

Solicitante:

AMGEN INC [US]

Resumen de: US2019142957A1

The present invention provides stable pharmaceutical compositions of pegylated carfilzomib compounds, methods for preparing the compositions, and uses of the compositions for treating cancer, including hematologic malignancies such as multiple myeloma. The compositions can be stored in frozen form or lyophilized to dry solid form.

traducir

N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS

NºPublicación: US2019144447A1 16/05/2019

Solicitante:

REDX PHARMA PLC [GB]

Resumen de: US2019144447A1

Disclosed are compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example, in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.

traducir

TREATMENT OF CNS LYMPHOMA AND SYSTEMIC LYMPHOMA WITH INTRACEREBROVENTRICULARLY ADMINISTERED CD19 CAR

NºPublicación: WO2019094498A1 16/05/2019

Solicitante:

HOPE CITY [US]
WANG XIULI [US]
FORMAN STEPHEN J [US]

Resumen de: WO2019094498A1

An improved method of treating cancers CD19 CAR T cells by administering the CD19 CAR T cells to the central nervous system, e.g., by intracerebroventricular administration, is described.

traducir

T CELL RECEPTOR-LIKE ANTIBODIES SPECIFIC FOR A WTI PEPTIDE PRESENTED BY HLA-A2

NºPublicación: US2019144563A1 16/05/2019

Solicitante:

MEMORIAL SLOAN KETTERING CANCER CENTER [US]
EUREKA THERAPEUTICS INC [US]

EP_3323833_A1

Resumen de: US2019144563A1

The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.

traducir

C3D CELLULAR AND ACELLULAR VACCINES FOR THE PREVENTION AND TREATMENT OF CANCER

NºPublicación: US2019144514A1 16/05/2019

Solicitante:

UNIV MICHIGAN REGENTS [US]

WO_2017189281_A1

Resumen de: US2019144514A1

The present invention relates to the treatment of cancer and to the prevention of cancer growth and/or metastasis. In particular, the invention relates to cellular and acellular vaccines containing C3d, a proteolytic product of complement (C3), and methods of enhancing a host immune response (e.g., a T cell mediated immune response) against cancers using same. Compositions and methods of the invention find use, alone or in conjunction with other cancer therapies, in treating lymphoma and/or cancers that develop and/or persist by evading host immune surveillance and/or responses (e.g., T-cell mediated immune responses). Compositions and methods of the invention find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.

traducir

Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma

NºPublicación: AU2017353427A1 16/05/2019

Solicitante:

ENGMAB SARL

WO_2018083204_PA

Resumen de: AU2017353427A1

The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ɛ (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma..

traducir

Inhibitors of cyclin-dependent kinase 7 (CDK7)

NºPublicación: AU2019202838A1 16/05/2019

Solicitante:

SYROS PHARMACEUTICALS INC

AU_2014337067_A1

Resumen de: AU2019202838A1

The present invention provides novel compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labelled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

traducir

ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH

NºPublicación: WO2019094772A1 16/05/2019

Solicitante:

UNIV MICHIGAN REGENTS [US]

US_2019144442_A1

Resumen de: WO2019094772A1

Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.

traducir

ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH

NºPublicación: WO2019094773A1 16/05/2019

Solicitante:

UNIV MICHIGAN REGENTS [US]

US_2019144442_A1

Resumen de: WO2019094773A1

Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

traducir

BIOMARKER FOR OUTCOME PROGNOSIS OF LENALIDOMIDE AND DEXAMETHASONE THERAPY IN MULTIPLE-MYELOMA PATIENTS

NºPublicación: WO2019093585A1 16/05/2019

Solicitante:

CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION [KR]

Resumen de: WO2019093585A1

The present invention relates to a biomarker for outcome prognosis of lenalidomide and dexamethasone therapy in multiple-myeloma patients, and, more specifically, provides: a biomarker for outcome prognosis of lenalidomide and dexamethasone therapy in multiple-myeloma patients; a composition for outcome prognosis of lenalidomide and dexamethasone therapy in multiple-myeloma patients, which comprises a primer or probe that specifically binds to the biomarker; a kit for outcome prognosis of lenalidomide and dexamethasone therapy in multiple-myeloma patients, which comprises a primer or probe that specifically binds to the biomarker; a method for providing information on outcome prediction of lenalidomide and dexamethasone therapy; and a method for outcome prediction and treatment of lenalidomide and dexamethasone therapy.

traducir

BCL9 PEPTIDES AND VARIANTS THEREOF

NºPublicación: WO2019094733A1 16/05/2019

Solicitante:

WNTRX PHARMACEUTICALS INC [US]

Resumen de: WO2019094733A1

Disclosed here are polypeptides derived from the HD2 domain of human B-cell CLL/lymphoma 9 (BCL9) protein and variants thereof, as well as their use in the diagnosis, prevention, and/or treatment of a disease or disorder. Also disclosed are methods of generating such polypeptides and variants thereof.

traducir

ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH

NºPublicación: US2019144442A1 16/05/2019

Solicitante:

UNIV MICHIGAN REGENTS [US]

US_2019142961_A1

Resumen de: US2019144442A1

Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

traducir

ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH

NºPublicación: US2019142799A1 16/05/2019

Solicitante:

UNIV MICHIGAN REGENTS [US]

CA_3024556_A1

Resumen de: US2019142799A1

Provided herein are small molecule inhibitors of ASH1L activity and small molecules that facilitate ASH1L degradation and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

traducir

ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH

NºPublicación: US2019142961A1 16/05/2019

Solicitante:

UNIV MICHIGAN REGENTS [US]

US_2019144442_A1

Resumen de: US2019142961A1

Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.

traducir

Monoclonal Antibodies That Specifically Recognize Canine DLA-DR Antigen and Their Uses

NºPublicación: US2019144560A1 16/05/2019

Solicitante:

INST IMMUNOLOGII I TERAPII DOSWIADCZANEJ POLSKIEJ AKDEMII NAUK [PL]

WO_2017151000_A1

Resumen de: US2019144560A1

Disclosed are monoclonal antibodies and their fragments that specifically recognize canine DLA-DR antigen and their use in the treatment, prevention, or diagnosis of leukemias and lymphomas, especially canine.

traducir

POLYNUCLEOTIDES ENCODING IL-31 MONOCLONAL ANTIBODIES

NºPublicación: US2019144533A1 16/05/2019

Solicitante:

ZYMOGENETICS INC [US]

US_2017355763_A1

Resumen de: US2019144533A1

The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions.

traducir

PURINONE COMPOUNDS AS KINASE INHIBITORS

NºPublicación: US2019144451A1 16/05/2019

Solicitante:

PHARMACYCLICS LLC [US]

Resumen de: US2019144451A1

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

traducir

SPIRO THREE-MEMBERED RING, SPIRO FIVE-MEMBERED RING PEPTIDE DEFORMYLASE INHIBITOR AND USE THEREOF IN ANTIBACTERIA AND ANTI-TUMOUR.

NºPublicación: EP3483155A1 15/05/2019

Solicitante:

RUDONG RUIEN PHARMACEUTICAL TECH CO LTD [CN]

Resumen de: EP3483155A1

Disclosed are the anti-bacterial activity and the anti-tumor activity of a class of new spiro three-membered ring and spiro five-membered ring peptide deformylase inhibitor. The spiro three-membered ring and spiro five-membered ring peptide deformylase inhibitor of the present invention, as a class of new anti-bacterial agent, are effective against many antibiotic-resistant Gram-positive strains by inhibiting the activity of the peptide deformylase required in the synthesis of bacterial proteins, and do not affect the synthetic process of the main proteins of the human body, thus selectively killing bacteria. The spiro three-membered ring and spiro five-membered ring peptide deformylase inhibitor of the present invention, as a class of new anti-bacterial agent, can affect the energy balance of the cancer cells through inhibiting the peptide deformylase of the mitochondria in the cells, so that the mitochondrial membrane is depolarized, ATP is exhausted and cell apoptosis is promoted, and has good inhibitory activities on many cancer cell strains such as colorectal cancer, leukemia, lung cancer, gastric cancer, cervical cancer, breast cancer, prostatic cancer, liver cancer and osteosarcoma at relatively lower concentrations.

traducir

LEUKEMIA METHYLATION MARKERS AND USES THEREOF

NºPublicación: EP3481952A1 15/05/2019

Solicitante:

YOUHEALTH BIOTECH LTD [KY]
UNIV CALIFORNIA [US]

US_2019136327_A1

Resumen de: US2018010192A1

Disclosed herein are methods and kits for identifying a subject as having leukemia. Also provided herein are methods and kits for determining a leukemia subtype in subject. Further provided herein are methods and kits for determining the prognosis of a subject having leukemia and for determining the progression of leukemia in a subject.

traducir

METHODS FOR TREATING CUTANEOUS T-CELL LYMPHOMA (CTCL) WITH MIR-155 INHIBITORS

NºPublicación: EP3481404A1 15/05/2019

Solicitante:

MIRAGEN THERAPEUTICS INC [US]

WO_2018009855_A1

Resumen de: WO2018009855A1

The present invention provides compositions and methods for treating cutaneous T-cell lymphoma (CTCL) with intralesional administration of one or more miR-155 inhibitors. In certain embodiments, the intralesional administration of one or more oligonucleotide inhibitors of miR-155 reduces the redness, thickness, height, scaling, and/or surface area of one or more untreated lesions on the skin of said subject.

traducir

CANCER TREATMENT

NºPublicación: EP3483273A1 15/05/2019

Solicitante:

IONIS PHARMACEUTICALS INC [US]

MX_2015005587_A

Resumen de: EP3483273A1

In certain embodiments, methods, compounds, and compositions for treating B-cell lymphoma or hepatocellular carcinoma by inhibiting expression of STAT3 mRNA or protein in an animal are provided herein. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate B-cell lymphoma or hepatocellular carcinoma.

traducir

METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA

NºPublicación: WO2019089854A1 09/05/2019

Solicitante:

HARVARD COLLEGE [US]
MASSACHUSETTS GEN HOSPITAL [US]

Resumen de: WO2019089854A1

The disclosure relates to compositions, methods, and kits for treating leukemia, specifically acute myeloid leukemia, in a subject, and for detecting chemoresistant acute myeloid leukemic cells.

traducir

PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ACUTE MYELOID LEUKEMIA OR METASTATIC BREAST CANCER

NºPublicación: WO2019088677A1 09/05/2019

Solicitante:

GWANGJU INST SCIENCE & TECH [KR]

Resumen de: WO2019088677A1

The present invention relates to a pharmaceutical composition comprising an indirubin derivative as an effective ingredient for prevention or treatment of acute myeloid leukemia or metastatic breast cancer. When used, the composition of the present invention can effectively inhibit the activity of FLT3 kinase and can be usefully applied to the prevention or treatment of acute myeloid leukemia or metastatic breast cancer.

traducir

TREATMENT OF ACUTE MYELOID LEUKEMIA

NºPublicación: WO2019088039A1 09/05/2019

Solicitante:

TAKEDA PHARMACEUTICALS CO [JP]

Resumen de: WO2019088039A1

This disclosure provides methods for treating AML. In particular, this disclosure provides methods for treating AML including relapsed or refractory AML, comprising twice daily administering to a subject having AML, including relapsed or refractory AML about 30-100 mg of a compound of Formula (I). In some embodiments, the compound of Formula (I) has Formula (II).

traducir

CRISPR-CAS9 DELIVERY TO HARD-TO-TRANSFECT CELLS VIA MEMBRANE DEFORMATION

Nº publicación: WO2019089034A1 09/05/2019

Solicitante:

METHODIST HOSPITAL [US]

Resumen de: WO2019089034A1

The CRISPR (clustered regularly interspaced short palindromic repeats) -Cas (CRISPR-associated) nuclease system represents an efficient tool for genome editing and gene function analysis. It consists of two components: single-guide RNA (sgRNA) and the enzyme Cas9. Typical sgRNA and Cas9 intracellular delivery techniques are limited by their reliance on cell type and exogenous materials as well as their toxic effects on cells (for example, electroporation). The present invention introduces and optimizes a microfluidic membrane deformation method to deliver sgRNA and Cas9 into different cell types and achieve successful genome editing. This approach uses rapid cell mechanical deformation to generate transient membrane holes to enable delivery of biomaterials in the medium. The present invention has achieved high delivery efficiency of different macromolecules into different cell types, including hard-to-transfect lymphoma cells and embryonic stem cells, while maintaining high cell viability. With the advantages of broad applicability across different cell types, particularly hard-to-transfect cells, and flexibility of application, this method can enable new avenues of biomedical research and gene targeting therapy such as mutation correction of disease genes through combination of the CRISPR-Cas9-mediated knockin system.

traducir

Página1 de 4 nextPage por página

punteroimgVolver